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Figure S1. Sub-genomic CRISPR screen preparation. A. Cas9 expression in B-ALL cell line NALM6 and SEM prior to
CRISPR screen. B. FACS plot showing transduction of NALM6 Cas9.EGFP with the undiluted lentiviral vector library,
demonstrating effective production of virus with a high titer. C. Library preparation from the genomic DNA isolated from the
sorted cells as Reference library and from expanded cells for 4 weeks as Depletion library. D-E. Intra-cell line Correlation plot of
individual sgRNA variance-stabilized abundances in the reference and depletion libraries prepared in SEM and NALM6 cell lines
between biological replicates. F. Inter-cell line correlation plots of individual sgRNA variance-stabilized abundances in the
reference and depletion libraries prepared in SEM and NALM6 cell lines between biological replicates.
Figure S2
Figure S2. RBP genes expression in B-ALL cell lines. A. mRNA expression of RBP genes identified, measured by RT-
qPCR (USO1, EIF3E and EPRS). Data was normalized to 18S expression level and is represented as fold-change from
SEM cells, which are arbitrarily assigned a fold-change of 1. Cell lines examined include SEM, RS4;11 (carry the MLL-
AF4 translocation), and NALM6 and REH (do not carry the MLL-AF4 translocation). B. Western blot to study basal level
expression of USO1, EIF3E and EPRS in NALM6, SEM and RS4;11cells. C-E. RT-qPCR analysis of expression of USO1
(C), EIF3E (D), and EPRS (E) in SEM, RS4;11 and NALM6 cells treated with 0.5 µM EPZ5676. F. RT-qPCR analysis of
USO1 in murine bone marrow cells with overexpression of MLL-Af4 (control versus MLL-AF4 bars). G-H. UCSC
genome browser shots of the EIF3E and EPRS loci showing the MLL-AF4 ChIP site(s) in the regulatory region as identified
from the ChIP-Seq data from Lin et. al.(ref #21 ); Courtesy: UCSC Genome Browser). Shown are the H3K27Ac track in
hematopoietic K562 cells (Blue), and MLL-AF4 binding sites represented as a grayscale score, with black indicating the
highest score/highest number of reads from the dataset.
Figure S3
Figure S3. Targeting USO1 in B-ALL cells. A. Plot of insertions and deletions by position near the Cas9 cut site in SEM cells
targeted with USO1 sg3; as determined by Tracking of Indels by Decomposition (TIDE). Genomic sequence aberration is highest
immediately adjacent to the cut site (designated as 0). B. USO1 depletion by transduction with sg3 in RS4;11 and SEM cells was
confirmed by Western blot analysis. C. RT-qPCR of USO1 mRNA expression level, expressed as fold-change, in RS4;11 and
SEM cells (t-test;*P < 0.05). D-G. Cell cycle analysis using propidium iodide (PI) of control cells (NT) and USO1-depleted cells
(D, E, respectively) following treatment with 1mM I-BET151. F-G. Quantitation of cells from cell cycle analysis in Sub-G0 (F)
and G0/G1 (G) at 2 different concentrations of I-BET151(t-test; *P < 0.05, **P< 0.001).
Figure S4
Figure S4. Modulation of USO1 expression by siRNA mediated knockdown. A. RT-qPCR analysis of USO1 expression levels,
expressed as fold-change, in SEM cells that were subjected to nucleofection with a control siRNA or siRNA_1 or siRNA_4. B-C.
Apoptosis induction, as measured by Annexin V staining, in SEM cells that were transduced with USO1-siRNAs. D-E. Cell cycle
analysis, using propidium iodide staining, of USO1-siRNA-treated cells. F. MTS assays (Absorbance at 490nm) measuring the
growth over time (days) of USO1-siRNA-treated SEM cells. (T-test; *P < 0.05, **P< 0.001).
Figure S5
Figure S5. GO Molecular function analysis from RNA-Seq data. A-B. Differential expression analysis of USO1 depleted
SEM cells analyzed by GSEA with msigDB Hallmark gene sets and the GO Molecular function dataset, show enrichment of
multiple RNA homeostasis related pathway. C. Venn diagrams showing overlap of USO1-negatively correlated genes in Target-
Phase II ALL dataset with the genes that are significantly downregulated or upregulated in USO1 depleted SEM cells. See
Figure 4 for assumptions utilized in the Hypergeometric test. D. Enrichment analysis of the genes downregulated in USO1
depleted cells that also have a high positive correlation with USO1 using Metascape. The data shows enrichment of several
cancer-relevant pathways.
Figure S6
Figure S6. Correlation of USO1 with experimentally downregulated genes following USO1 knockdown. A-D. Genes
downregulated in USO1 depleted SEM, including PSMD1, ABCA1, BTAF1 and MRPS12 show a strong positive correlation
with USO1 expression in clinical B-ALL samples (Courtesy: cBioPortal).
Figure S7a. Primary Western Blot Data. Each sub-panel lists the corresponding main panel in the main
figures. These panels are the portion of the Western Blot scanned image that corresponds with the experiment
being performed. In other cases, panels are showing the portion of a scanned image obtained by imaging on a
ChemiDoc Imaging system from Biorad.
Corresponding to Fig.2d









Corresponding to Fig. 4e
pMTOR




Corresponding to Fig. S3b
USO1 EPRS EIF3E
Corresponding to Fig. S2b
Figure S7b. Primary Western Blot Data. Each sub-panel lists the corresponding main panel in the main
figures. These panels are the portion of the Western Blot scanned image that corresponds with the experiment
being performed. In other cases, panels are showing the portion of a scanned image obtained by imaging on a
ChemiDoc Imaging system from Biorad.
Figure S7b
Vinculin
Gene Name Guide RNA sequence 
IGF2BP3 AGCTTGGTCCTTACTGGAAT 
IGF2BP3 AAGCACCAGATGCTAAAGTG 
IGF2BP3 C CAC CGT AAA GAA AAT GCG G 
IGF2BP3 A GGC GCA GAG GCA AAT CAC A 
IGF2BP3 G CTG GGC GGC CAT TTC ATC A 
BAZ1A C AGT GCA TAA GCC AAA TCG G 
BAZ1A T GGT GTC AAA TCA TAC ACT G 
BAZ1A T CCA GTA TCG TCT ATA CAT G 
BAZ1A G TAA GCG CGA ACG ATG GGT A 
BAZ1A T TTC CTG ATG GAG TAA CCC T 
USO1 A GGG TGA TAA GAT CGA CAG A 
USO1 G GAC TTA CTA GCG GAT TCC A 
USO1 A GCT ACT GGT AGC ACC AGG A 
USO1 T CAG CTG GCC AGT TAT TAT G 
DDX3Y TATGAACACCACTACAAGGG 
DDX3Y C AGA TTC GGG ACT TAG AAC G 
DDX3Y C AGT TTA GCG ATA TTG ACA T 
DDX3Y A TGA TAA AGA CAG TTC AGG T 
DDX3Y G TAT ATA TCT GAC TCA GTA T 
MBNL1 G TAT GTC GAG AGT ACC AAC G 
MBNL1 CAACGTGGCAATTGCAACCG 
MBNL1 C TTG GTG CAA CTG AAA ACA T 
MBNL1 G TAA CCA ACA TTG GTG CAG T 
MBNL1 T GCC CAA TAC CAG GTC AAC C 
TUBB6 G CTG ACA ACG CCC ACC TAC G 
TUBB6 C AGC TGG TGC ACC GAC AGT G 
TUBB6 C CAT GGC CGC TAC CTG ACC G 
TUBB6 C TGG CCC GGG AAG CGC AGC G 
TUBB6 GTTGCAGGCCAGACGGGTGC 
DDX21 C CTA CAT TCA TCG ATC CGG G 
DDX21 G CAA CAT TAA ATA CCC AAT G 
DDX21 G ATG TCA TCC GAG TAT ATA G 
DDX21 C ATC ACA AAA AAG CTG TCA G 
DDX21 CTAGTTTGCCATTCTGTATG 
LUC7L3 G TAG AAC GTA GGA TCA GAC G 
LUC7L3 C ATC AAA TGG TCA TCT ACC C 
LUC7L3 G TAT TTG TGA ACA ATT CCG C 
LUC7L3 T TTA GAC GCT CAT CAC GAT C 
LUC7L3 A ACT AAT TTC ATC ATC CCC T 
LARP7 T GGA AGG CAC CAG AAT CCG G 
LARP7 A TCA CTC CAC TCA CGA ACT G 
LARP7 A GAC TAT CAG GAT CCG GAG A 
LARP7 T GCT AGA TTT AAA ACT CCT G 
LARP7 GAGAAGTTCAGCTGTTGTAG 
IQGAP1 C TAC GCG TCC AAC CAG CGA G 
IQGAP1 ATCAGCGGAGGTACCGACAG 
IQGAP1 C CTG TCG AAC TAA GTA TCC A 
IQGAP1 G AAT GAT ATC CAA GCT TGC G 
IQGAP1 CCGTGGATACTTAGTTCGAC 
CSTF3 C TCC TTC CTC ACC TGC TCC G 
CSTF3 G CTG AGG CCA TGT CAG GAG A 
CSTF3 C CCA GAG AAG GTG AAG AAA G 
CSTF3 A GCT GAG TAT GTC CCA GAG A 
CSTF3 GGTTTACACCCTGTACCTGG 
EPRS A ATG TAT ATC AAA ACA CAC G 
EPRS C ATG TTC ACG ACT GAA CGT G 
EPRS C TCC AGT TCA TGT AAA ACG T 
EPRS A GAA TGC TTA CTG TCC CTG A 
EPRS A GTA GAG TAT AAG CCT GTG T 
ANXA1 GGTGACGCAGAACTCCCCTG 
ANXA1 T CAC ACC AAA GTC CTC AGA T 
ANXA1 AGACCTTCGACGTGAATCGC 
ANXA1 C CTT ACA GGT CAC CTT GAG G 
ANXA1 A AAA TCT CCA GAT GTG TCT G 
EIF3E T ACA GCA GTC ATA ACA AAC A 
EIF3E T AAT ATT ATC GCG ACC TTT G 
EIF3E  CTT CTT AGT GAT ACC AAC A 
EIF3E A ATG CTT TAA GTT CAC TCT G 
EIF3E C AAA ATT CCA GTA CGA ATG T 
ANXAP21 C AGG GAC TGC TAG TCA CAA G 
ANXAP21 GGATCAGCGTCATGACCGAG 
ANXAP21 A AGG AAC TGA AGT TCC CAA G 
ANXAP21 T GAC TGA CCC AAA TGC ACT T 
ANXAP21 G TTA GTC AAA ATG TTG ACA G 
CAMK2B C ACC GTC ATC CAT AAC CCA G 
CAMK2B C TCA CCT GAG AAA TTC CGT G 
CAMK2B G GCG AGA GAG TAC TAC AGC G 
CAMK2B G TGC ATC ATG GAT GCT ACC G 
CAMK2B C TCT TTG CGA AGG ACC TCA G 
PAICS A TTG GAA TCA TTT CAC ACT G 
PAICS T ACG AAT TGT TAG ACA GTC C 
PAICS G CTA GAA AAA ACC ACC TGG A 
PAICS A TGC CAA TAA TGA CCC ACA G 
PAICS C TTA CGA TTT GAC TTA TAT G 
FLNA C GTC AAA GCA GGG AAC CAC G 
FLNA A GTG GAG TAC ACG CCT TAC G 
FLNA T GGT GAC GAT ATA GGT TCC A 
FLNA A GTC GAT GTC AGC TTC GGC G 
FLNA T TAT CCA CGT ACA CCT CGA A 
SLTM A AAC CTC TTT GCT TGA CCA G 
SLTM A ACT ATG TCT TCA AGC ACA G 
SLTM G CAT TAG AAT AAT TCG TGA A 
SLTM T CTA ATG TAG GCT ATT GAA G 
AHNAK G GGC CCA AGT ATG AAC ATT G 
AHNAK G TGA TGC TAC CCC CAA TTT G 
AHNAK G GCT CTT CAA GTG TAG ATC G 
PPIG T CTG GAC GGA CAG TAG ACT G 
PPIG G TGG TGA AAG ATG GAT CAA G 
PPIG A GCT AGC AAA CCG TTT GCG G 
PPIG G GAG GGG AAT CTA TCT ATG G 
PPIG A AAG GGC CAA ATC TAA AAG T 
BAG2 T CAA CGC TAA AGC CAA CGA G 
BAG2 T CCA AAA TAG CCA GGA CAT G 
BAG2 C ACC TCA TCA ATA ATC CTT G 
BAG2 G AGC GAC ATT AAA TGA CTC T 
BAG2 GATCAACGCTAAAGCCAACG 
MSH2 C TGT CTC TGG CCA TCA ACT G 
MSH2 C ATG GAT AAG AAC AGA ATA G 
MSH2 A GGG GGT GAT CAA GTA CAT G 
MSH2 A CAT CAT TGA GTG TCT GCA T 
LMNA GCGCCGTCATGAGACCCGAC 
LMNA C CGT CAT GAG ACC CGA CTG G 
LMNA A GTT GAT GAG AGC CGT ACG C 
LMNA G GAC AGA GAC TGC TCG GAG T 
ANAPC4 C CTG CAG CAT CTA GTC CAA G 
ANAPC4 G TCA CAG AAG TCT CTA CCA A 
ANAPC4 CTCAAAATGCATGGTACGGG 
ANAPC4 AAAGACACTGTAGGACGTGA 
RAD50 C TAG GAA CGT GAG TTA AGC A 
RAD50 A AGC GGC GTG ATG AAA TGC T 
RAD50 A AAC AGC ACA AGT TAG ACA C 
RAD50 A AAA ACT GCC AAC CAA CTG A 
RAD50 T ACA TTT GTA CAC GAT CCC A 
VIM A CAG CAT GTC CAA ATC GAT G 
VIM TCCTACCGCAGGATGTTCGG 
VIM A GAA GAA TGG TAC AAA TCC A 
VIM C AAC GAC AAA GCC CGC GTC G 
VIM C TCT ACG CCT CGT CCC CGG G 
S100A10  G GAT AAA GGC TAC TTA ACA A 
S100A10 A TCT CAA ATG GAA CAC GCC A 
S100A10 G GAG GAC CTG AGA GTA CTC A 
S100A10 C ACT TAC TTC CAA AAA TCC A 
S100A10 G GAC AAA ATA ATG AAG GAC C 
PALLD A CGA AAA CTT CGC TTC AAG G 
PALLD G CTG CTG AGA GGG AAA CGA A 
PALLD G AGG CCT TTG AGG ACG ACA C 
PALLD G GAA CTG CAA AAC ACA GCC G 
PALLD A CCT GAG GTG ACA ACC AGC T 
SKIV2L2 T CTG TGT AAA TAA CAT GAC A 
SKIV2L2 T GTT GAA GGG TGT ACA CAT G 
SKIV2L2 T TGT CTT GTT ATG ACC ACA G 
SKIV2L2 T TTC CAT TTG ACC TAC AAC A 
SKIV2L2 A CCA AAT TAG ATT TCA ACA C 
SMARCAD1 A TGA CCG TAG TCT GTT TCG A 
SMARCAD1 T GTC GGT AGT TCA CTA GAT G 
SMARCAD1 C TGG CAT ACC TCT ATC AGG A 
SMARCAD1 T GCA TCA CCA AAC ATC AGC A 
SMARCAD1 A CCT CCA TTT CCA GTA AGC A 
OGT T GGC AAT AGA CAC CTA CAG G 
OGT G CCA ATA TCA AAC GAG AAC A 
OGT T GGC ACA AAC TTC CGA GTG A 
OGT G GCA CGC GTA TAA CAC TGC A 
OGT C TAT ACA CTT CCA GTG TCG A 
C1QBP G GCC CGC TAA ACC TCA CCG T 
C1QBP A TTA GTG CGG AAA GTT GCC G 
C1QBP G CGT GCG CGC AGG TTC CGA G 
C1QBP G ATA ATG ACA GTC CAA CAC A 
C1QBP GGACAGAAGCGAAATTAGTG 
HSPD1P6 G AAA GCT TGA AGT TTG ATC G 
HSPD1P6 G GTC TTA TCT AAA GAC AGT G 
HSPD1P6 T AGC TAT GCC AAA GGT TGG T 
HSPD1P6 C ACC CCT GAA GAA ATT GCG C 
HSPD1P6 A TAA TCA CTG AAG ATG TTG G 
PSDM14 A AAC ACA TCA ATC ACT CTG A 
PSDM14 A AAG CCA ACA ACC AAA GCC A 
PSDM14 A TCA AAC CCA TAA CTT CCA T 
PSDM14 A GAC AAA CAA CTT CGA ATC T 


































































BCL-2  GGCCTTCTTTGAGTTCGGTG 
BCL-2  TGGACATCTCGGCGAAGTCG 
BCL-2  TGTCGCAGAGGGGCTACGAG 
BCL-2 CTGACGCCCTTCACCGCGCG 































Table S1. Short guide RNA (sgRNA) sequences.  
Genes Primer Sequence 
USO1-Forward Primer TACCGCTTGGAAGTGGGTAT 
 
USO1-Reverse Primer AAATCTTCACTCTGTCTTGTGGAAT 
 
EPRS- Forward Primer GGG AAG GCT TAT GTG GAT GA 
 






MRSP12-Forward Primer CCTCTTCCATCAGGACCACT 
 
MRSP12-Reverse Primer CAGTGTCTTGTCCCAGCAG 
 
TRFC-Forward Primer TGGACAGCACAGACTTCACC 
 
TRFC-Reverse Primer CCAGGATTCTCCACCAGG 
 
NOP16-Forward Primer AGGGTGTAAGGCAAGGAGGT 
 
NOP16-Reverse Primer ATCACCCACCCTGAAAACA 
 
DDX21-Forward Primer GCAGCAGTTATTGGGGATGT 
 
DDX21-Reverse Primer TGAATTCTGGGACAGCTCCT 
 
PSMD1-Forward Primer CTGTGGTTGGCGTCCTTGTAT 
 
PSMD1-Reverse Primer CAAATGTGGATGGTTTACAG 
 
Human 18s Forward Primer GTAACCCGTTGAACCCCATT 
 
Human 18s Reverse Primer CCATCCAATCGGTAGTAGCG 
 
Uso1-Forward Primer CCAGGGAAGCAAAATACAGA 
 
Uso1-Reverse Primer GCACATAAGCCTTGGACC 
 
L-32 Forward Primer AAG CGA AAC TGG CGG AAA C 
 
L-32 Reverse Primer TAA CCG ATG TTG GGC ATC AG 
 
 
Genes ChIP primer sequence 
USO1-Fw TGGCTGAACGGCAAGATGAAT 
 
USO1- Rev CTGGGATTTCAGGAGCGGA 
 
 
Genes sgRNA sequence 










CRISPR Lib. primers Sequence 
Part I Illumina Universal Adaptor 
with variable region and vector 
seq. 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTT
AA TGGAAAGGACGAAACACCGA  
 
PartII Illumina Index adaptor GACTGGAGTTCAGACGTGTGCTCTTCCGATCTT
TTAGTTTGTATGTCTGTTG 
 
Rest Illumina universal adaptor AATGATACGGCGACCACCGAGATCTACACTCTT
TCCCTACACGACGC 
 




Table S2. Primer sequences.  Please see text for details. 
